Freeline Therapeutics Holdings plc announced that Paul M. Schneider has been appointed Chief Financial Officer (CFO), effective May 16, 2022, based in Boston. Mr. Schneider joins Freeline from Exo Therapeutics Inc., where he served as Senior Vice President, Finance and Operations. A seasoned financial executive with more than 20 years of leadership experience in large and small private and public biopharmaceutical companies, Mr. Schneider brings an impressive track record of financial stewardship, including corporate strategy and execution, financial planning, analysis and reporting, and investor relations, to Freeline.

Prior to joining Exo Therapeutics Inc. in 2020, Mr. Schneider was Senior Vice President, Finance at Casebia Therapeutics, LLC. Before joining Casebia, he held senior finance positions at Aegerion Pharmaceuticals Inc., Systagenix Wound Management Ltd., Shire Human Genetics Therapies Inc., and Transkaryotic Therapies Inc.Mr. Schneider holds a Bachelor of Science degree in Accounting from Boston College and earned his Certified Public Accountant license in Massachusetts.